2024 News Releases

April 18, 2024 - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Read

April 3, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

Mar. 20, 2024 - Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Read

Feb. 29, 2024 - Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
Read

Feb. 27, 2024< - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

Feb. 22, 2024 - Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
Read

Feb. 15, 2024 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Read

Feb. 13, 2024 - Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
Read

Jan. 11, 2024 - Puma Biotechnology to Present at B. Riley Securities 4 th Annual Oncology Conference
Read

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax